Last reviewed · How we verify
NCT03872661: NIBCUN
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2 trial testing IBI308 in Lung Cancer Stage III in 36 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 March 2019 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- IBI308
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- Pemetrexed — full drug profile →
- Carboplatin (Carboplatin) — full drug profile →
- Thoracic surgery
Conditions studied
- Lung Cancer Stage III — all drugs for Lung Cancer Stage III →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, any sex, with Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J, Zhang C, Zhong WZ. · · 2021 · cited 121× · PMID 33689225 · DOI 10.1002/cac2.12153 -
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
Godoy LA, Chen J, Ma W, Lally J, et al · · 2023 · cited 34× · PMID 36650586 · DOI 10.1186/s40364-022-00444-7 -
Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges.
Kalvapudi S, Vedire Y, Yendamuri S, Barbi J. · · 2023 · cited 19× · PMID 38144524 · DOI 10.3389/fonc.2023.1286104 -
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.
Qiu B, Cai K, Chen C, Chen J, et al · · 2021 · cited 17× · PMID 34733623 · DOI 10.21037/tlcr-21-634 -
Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.
Fu Y, Duan W, Xu R, Chen J. · · 2023 · cited 1× · PMID 38022567 · DOI 10.3389/fimmu.2023.1268153
Verify or expand the search:
- PubMed search for NCT03872661
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IBI308
Trials testing the same drug.
- NCT04277663 — The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has · Phase 3 · terminated
- NCT04056949 — Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy · Phase 2 · unknown
- NCT03732430 — CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients · Phase 2 · unknown
- NCT03568539 — IBI308 in Subjects With Advanced/Metastatic Solid Malignancies · Phase 1 · completed
- NCT03150875 — A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC · Phase 3 · completed
Other recruiting trials for Lung Cancer Stage III
Currently open trials in the same condition.
- NCT06968221 — Bovine Reinforcement in Stomach, Colorectal and Lung Operation · Phase 3 · recruiting
- NCT06563999 — Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · Phase 2 · recruiting
- NCT06111807 — Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03872661 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 6 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03872661.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing